Biotech and Pharmaceutical Patents at the Federal Circuit

Biotech and Pharmaceutical Patents at the Federal Circuit

Speaking Engagement
Join join other members of the local biotech, medical device and pharmaceutical industry for breakfast and a seminar discussion with Tara Elliott and Peter Fasse, who will recap several 2013 legal developments relevant to your industries.

Tara and Peter will provide their views on several federal court decisions including: Section 101 patent eligibility of human genes under Myriad, Section 102 novelty and prior public use of drugs under Pronova Biopharma, Written Description of enzyme variants under Novozymes, Patent Exhaustion under Bowman, parallel litigation and reexamination strategies under Fresenius, and more. They will put these cases into context and provide important advice on how they may impact both your prosecution and litigation strategies. 

Read More About the Event


Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.